The European medicines agencies network strategy to 2028 is available below.
The strategy equips the European medicines regulatory network to respond to change and address challenges such as public health emergencies and threats, including antimicrobial resistance.
It focuses on six areas:
- Accessibility – facilitating access to medicines in the EU
- Leveraging data, digitalisation and artificial intelligence – improving decision-making, optimising processes and increasing efficiency
- Regulatory science, innovation and competitiveness – helping improve innovation and competitiveness in the EU healthcare sector
- Antimicrobial resistance and other health threats – preparing the EU for potential threats including antimicrobial resistance
- Availability and supply – strengthening availability of medicines to protect public and animal health
- Sustainability of the European medicines agencies network – ensuring available resources to support its scientific and regulatory decision-making
The updated network strategy to 2028 builds on the strategy to 2025.
It places greater emphasis on the competitiveness of the EU in developing and manufacturing medicines, ensuring they are accessible and available to EU citizens while leveraging artificial intelligence.
It also highlights the One Health approach, recognising that the health of humans, animals and the wider environment are closely linked.
EMA and the Heads of Medicines Agencies (HMA) adopted the final strategy in March 2025.
They also published a summary of the public consultation results. This public consultation took place between October and November 2024.